• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [6756 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2022 Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022 Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022 Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: helicopter emergency medical services (HEMS) - needs analysis and clientele identification]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: molecular profiling of adult solid tumors - Focus Panel (Illumina) – 52 somatic biomarkers analysis]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Evaluation of Fibryga (human fibrinogen concentrate) – acquired fibrinogen deficiency]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy of psychosocial interventions for the prevention and treatment of common mental disorders and symptoms]
2022 Ontario Health Mechanical thrombectomy for acute and subacute blocked arteries and veins in the lower limbs
2022 Norwegian Institute of Public Health (NIPH) [Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2022 Norwegian Institute of Public Health (NIPH) [Overdose warning systems: a single technology assessment - mapping]
2022 Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022 Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022 Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022 Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022 Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022 Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022 Agency for Care Effectiveness (ACE) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for chronic lymphocytic leukaemia
2022 Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022 Health Information and Quality Authority (HIQA) Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022 Institute for Clinical and Economic Review (ICER) Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022 Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
2022 Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2022 NIHR Health Technology Assessment programme Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022 NIHR Health Services and Delivery Research programme Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: Hereditary Cardiovascular diseases NGS Panel - Evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: service trajectories and services for at risk or neglected children and their families]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: issues pertaining to the implementation of a clinical decision support system for diagnostic test ordering]
2022 Center for Drug Evaluation (CDE) The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
2022 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Portable home hemodialysis systems]
2022 Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022
2022 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at commerce in controlling the spread of COVID-19]
2022 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at workplaces in controlling the spread of COVID-19]
2022 Austrian Institute for Health Technology Assessment (AIHTA) Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2022 Austrian Institute for Health Technology Assessment (AIHTA) Subcutaneous implantable cardioverter-defibrillator (S-ICD). Update 2022
2022 Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous transvascular implantation of a coronary sinus reducing stent. Update 2022
2022 Austrian Institute for Health Technology Assessment (AIHTA) Hepatic and portal vein embolisation prior to major hepatectomy
2022 Austrian Institute for Health Technology Assessment (AIHTA) Microwave ablation for liver tumours
2022 Austrian Institute for Health Technology Assessment (AIHTA) His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation
2022 Austrian Institute for Health Technology Assessment (AIHTA) Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer
2022 Austrian Institute for Health Technology Assessment (AIHTA) Lower esophageal sphincter devices for laparoscopic surgery in patients with gastroesophageal reflux disease (GERD)
2022 Health Technology Wales (HTW) Convalescent plasma therapy for the treatment of COVID-19
2022 Health Technology Wales (HTW) Extreme hypofractionated radiotherapy (EHFRT) for localised prostate cancer
2022 Austrian Institute for Health Technology Assessment (AIHTA) [Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]
2022 Health Technology Wales (HTW) Video laryngoscopes for use in pre-hospital care
2022 Health Technology Wales (HTW) Electronic blood management systems for blood transfusions
2022 Health Technology Wales (HTW) Stereotactic ablative radiotherapy (SABR) for the treatment of renal cell carcinoma
2022 Health Technology Wales (HTW) Laryngeal biopsies in the outpatient setting in people with suspected head and neck dysplasia/cancer
2022 Penn Medicine Center for Evidence-based Practice (CEP) VTE chemoprophylaxis for patients undergoing elective spinal surgery
2022 Penn Medicine Center for Evidence-based Practice (CEP) Video camera-assisted or electromagnetic placement of enteral feeding tubes
2022 Penn Medicine Center for Evidence-based Practice (CEP) Pneumocystis jirovecii pneumonia (PJP) prophylaxis
2022 Health Sciences Institute in Aragon (IACS) Efficacy, safety and efficiency of sentinel lymph node magnetic localisation techniques in breast cancer
2022 WorkSafeBC Dry needling for lateral elbow pain
2022 WorkSafeBC Efficacy and/or effectiveness of treatments for lateral epicondylitis - barbotage and ultrasonic tenotomy
2022 WorkSafeBC Fat grafting for nerve padding
2022 WorkSafeBC Intravenous ketamine for PTSD and treatment-resistant depression
2022 WorkSafeBC Sweat lodge usage as treatment for depression or other psychological disorders
2022 Norwegian Institute of Public Health (NIPH) Surgical procedures for treatment of obesity: health technology assessment
2022 Penn Medicine Center for Evidence-based Practice (CEP) Organizational strategies to improve or promote healthcare worker wellness
2022 Norwegian Institute of Public Health (NIPH) First trimester-screening for the development of preeclampsia with the use of an algorithm: a health technology assessment
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 2 - overview of liver transplantation in Québec]
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis, combination with rituximab or cyclophospha-mide)]
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ripretinib (gastrointestinal stromal tumours (GIST), ≥ 3 prior therapies)]
2022 Agency for Care Effectiveness (ACE) Guardant360 CDx for patients with locally advanced or metastatic non-small cell lung cancer
2022 Agency for Care Effectiveness (ACE) The Signatera test for patients previously diagnosed with cancer
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: somatic variant classification and stratification strategies]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: next generation sequencing hereditary cancer gene panels]
2022 Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022 Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022 Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022 Agency for Care Effectiveness (ACE) Nivolumab for treating gastroesophageal cancers
2022 Agency for Care Effectiveness (ACE) Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia
2022 Agency for Care Effectiveness (ACE) SGLT2 inhibitors for treating heart failure with reduced ejection fraction and chronic kidney disease
2022 Agency for Care Effectiveness (ACE) Cabozantinib in combination with nivolumab for previously untreated advanced renal cell cancer
2022 Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Solriamfetol (obstructive sleep apnoea) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albutrepenonacog alfa (haemophilia B) - Assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to adolescents)
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (Peanut allergy) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery for the treatment of patients with brain metastases]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (sleep apnoea) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A21-101]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stent retriever for the treatment of cerebral artery vasospasm after subarachnoid haemorrhage]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]